The investigator proposes studies with L-selectin down regulated CD8+ T cells in mice to see whether their effectiveness can be improved with cytokines, examine the histology of tumors to see where administered CD8+ cells traffic, whether they undergo apoptosis or become tolerated at the tumor site. Dose-response studies with various numbers of T cells will also be performed against established tumors. The use of dendritic cells with peptides will also be explored to immunize the mice from which the T cells are obtained. Treatment of the tumor with cyclooxygenase inhibitors will also be studied to see whether tumor-induced suppression can be overcome.
| Cohen, Peter A; Koski, Gary K; Czerniecki, Brian J et al. (2008) STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood 112:1832-43 |
| Zheng, Rongxiu; Cohen, Peter A; Paustian, Christopher A et al. (2008) Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 68:4045-9 |
| Peng, Liaomin; Kjaergaard, Jorgen; Plautz, Gregory E et al. (2002) Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol 169:4811-21 |
| Kjaergaard, J; Peng, L; Cohen, P A et al. (2001) Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol 167:6669-77 |
